background: Red blood cells (RBC) of patients with thalassaemia are under continuous oxidative stress. Fermented papaya preparation® (FPP®) has been shown to have an antioxidative effect and is postulated to reduce the oxidative stress on RBC.
bACkgrOund Thalassaemia is a congenital haemolytic anaemia resulting from partial or complete absence of one of the major α or β globin chains of HbA (α 2 β 2 ). It is the commonest genetic disease in South-East Asia. The incidence of α and β thalassaemia trait is 2.92% and 0.93%, respectively. The incidence of HbE, a haemoglobin variant due to mutation in the β globin gene which results in both quantitative and qualitative defect of the β globin chain, is 0.64% 1 . A child who inherits both HbE and β globin chain mutation may present with thalassaemia intermedia. Thalassaemia intermedia encompasses a broad clinical spectrum from mild anaemia to transfusion dependent anaemia. While iron loading is less accelerated than transfusional iron accumulation in patients with thalassaemia major, patients with thalassaemia intermedia Proceedings of Singapore Healthcare  Volume 19  Number 2  2010 often develop cardiac disease, hepatic fibrosis, endocrine abnormalities and other complications of iron overload due to increased gastrointestinal iron absorption 2 .
Red blood cells of patients with thalassaemia are under continuous oxidative stress 3 due to generation of high levels of reactive oxygen species (ROS) and reduced content, due to increased consumption, of anti-oxidants such as glutathione (GSH) 3, 4 . The causes of this stress are both intracellular (example, the presence of abnormal Hb and its degradation products, such as free globin chains, heme and free iron) as well as extracellular (example, iron overload). The oxidative stress has major deleterious effects mainly on the cell membrane. This results in the externalisation of phophatidylserine (PS) moieties-negatively charged phospholipids that have been shown to mediate erythrophagocytosis by macrophages in the reticuloendothelial system 5, 6 . It has been shown that thalassaemic RBC have abundant exposure of PS, which has been speculated to play a role in ineffective erythropoiesis (due to increased apoptosis of erythroid precursors) and short life span of mature RBC due to increased extravascular haemolysis 7 .
Fermented papaya preparation (FPP®) is a product of yeast fermentation of carica papaya linn. The composition of its principle components has been previously described 8, 9 . It has been shown to limit oxidative stress both in vitro and in vivo [10] [11] [12] [13] . Being an antioxidant, FPP® is expected to decrease the oxidative damage to thalassaemic mature RBC and erythroid precursors in the bone marrow and hence improve haemoglobin (Hb) levels in these patients. We have previously reported on in-vitro amelioration of oxidative stress in a heterogenous population of patients with β thalassemia major and intermedia, including HbE/ β thalassemia 9 .
We performed a pilot study to assess the clinical effects of FPP® treatment in patients with HbE/ β-thalassaemia on (1) RBC indices such as Hb, mean corpuscular volume (MCV), and reticulocyte count; (2) on oxidative stress parameters such as generation of ROS, GSH, lipid peroxidation within the RBC, and (3) quality of life scores.
METHOdS recruitment of Patients Inclusion Criteria
Patients with HbE/β thalassaemia who are on regular outpatient follow-up with KK Women's and Children's Hospital (KKH) with:
1. Baseline Hb <10g/dL, and 2. Patients who are not regularly transfused and did not receive transfusion at least 10 weeks prior to initiation of the study.
The study was approved by the institutional review board (IRB) of KKH. All patients or parents (for children less than 18 years) gave their written informed consent to participate in the study.
Patients were given 2 sachets (3gm per sachet = 6gm per day) of FPP® daily for 12 weeks. Peripheral blood samples (3ml blood, collected in ethylenediaminetetraacetic acid [EDTA] tube) were obtained at the initiation of the study and at 4 weekly intervals thereafter for a period of 12 weeks for complete blood count and cellular oxidative parameters.
Laboratory Methods

Complete Blood Count
Complete blood count, including Hb, MCV and reticulocyte count, was measured on the blood sample using Cell-dyne 3500 (Abbott, USA).
Cellular Parameters
For reactive oxygen species (ROS) assay, RBC were incubated with 2' ,7'-dichlorofluorescin diacetate (DCF) (Molecular Probes, Invitrogen, Carlsbad, California, USA), dissolved in methanol, at a final concentration of 0.4mM. Upon crossing the cellular membrane, DCF undergoes deacetylation by intracellular esterases producing a non-fluorescent compound that becomes highly green fluorescent following oxidation by ROS 14 . For glutathione (GSH) assay, RBC were incubated with 40μM of mercury orange. Mercury orange reacts with the SH group of GSH to produce red-orange fluorescence 14 RBC treated as above for the measurement of different oxidative parameters were analysed by a fluorescence-activated cell sorter, FACSCalibur™ (Becton Dickinson, San Jose, USA) using flow cytometric methods described previously by Amer et al 14 . The mean fluorescence channel (MFC) of the entire RBC population was calculated for ROS, GSH and lipid peroxidation by the FACSCalibur™ and CellQuest® software (Becton-Dickinson). The MFC of DCF-and mercury orange-stained cells was proportional to the ROS and GSH content, respectively, while that of fluor-DHPE-stained cells was reciprocal to their lipid peroxide content.
Quality of Life
Patients were given RAND 36-item Short Form Health Survey (SF-36) at the initiation and at the end of the study to assess for any change in their quality of life with FPP® treatment. SF-36 is a set of generic, coherent and easily administered quality-of-life measures. These measures rely upon self-reporting and are widely used by managed care organisations. The SF-36 includes questions on general health, physical functioning, role limitations due to physical health or emotional problems, energy level, emotional being, social functioning and pain. Each question is pre-assigned a score from 0 to 100 and a final score is calculated by adding up the individual scores, with a maximum score of 3,600. The questionnaires were administered in a standardised manner and were completed during the first and the last visits.
Statistical Analysis SPSS v14.0 (for Microsoft Windows) was used for statistical analysis. Wilcoxon sum rank test was used to compare the pre and post treatment parameters. Values are reported as mean (SD). The confidence interval was set at 95% and p<0.05 was considered as significant.
rESuLTS
Patient Characteristics
Seven patients were recruited in the study as illustrated in Table 1 . There were 5 females (71%) and the median age of the study cohort was 19 years (range 4 to 27 years). All patients had HbE/ β-thalassaemia and all had known β-thalassaemia mutations as shown in Table 1 . The mean baseline Hb was 7.7g/dL (1) . None of the patients had received blood transfusion within 10 weeks of the enrollment period.
Laboratory Parameters
Results of the parameters pre-and post-FPP® treatment are summarised in (Fig. 1) .
GSH Assay
The mean MFC of the unstimulated and H 2 O 2stimulated RBC were 114 (22.1) and 57 (15.8) , respectively, at baseline, and 218 (109.1), (p=0.028) and 157 (56.5), (p=0.018), respectively, after treatment with FPP® which indicate a significantly higher production of intracellular GSH (Fig. 2) .
Lipid Peroxidation
The mean MFC of the unstimulated and H2O2stimulated RBC were 99 (16.3) and 57 (12.6), respectively, at baseline, and 140 (19.6), (p=0.018) and 69 (22.4), (p=0.237), respectively, indicating a decrease in lipid peroxides after treatment with FPP®.
Quality of Life
Quality of life (QoL) assessment by the SF-36 health survey did not show any significant change with FPP® treatment as shown in Table 2 . Analysis of QoL scores by sub-headings also did not show any significant difference.
diSCuSSiOn
Oxidative damage has been associated with multiple health problems including metabolic, immunological and cardiovascular disorders as well as cancer 15 . There is evidence that antioxidants can ameliorate parameters of oxidative stress with consequent improvement in several clinical and laboratory parameters 16 . In thalassaemia, the initial abnormality is due to the impaired globin chain synthesis. However, the damage to various cellular components is at least partially mediated by oxidative stress 17 . GSH is considered an important scavenger of ROS and is a key component of the intracellular anti-oxidant system 14 . Initiation of lipid peroxidation by the oxygen-derived free radicals leads to oxidation of polyunsaturated fatty acids into lipid hydroperoxides. This is considered as a significant stage in the pathogenic process related to oxidative stress. FPP® ameliorated these However, despite the improvement in oxidative parameters, there were no significant improvements in the RBC indices (Hb, MCV or reticulocyte count), or in the quality of life.
One of the limitations of this study is the short study duration of 3 months. This period may not be sufficient to demonstrate an improvement in Hb concentrations and/or in quality of life. The dose of 6gm FPP® per day may not be enough and higher doses of FPP® may be required to show clinical improvement.
COnCLuSiOn FPP® significantly reduced parameters of oxidative stress in RBC of 7 patients with HbE/β-thalassaemia and was well tolerated by the patients. However, there were no significant effects on Hb levels or in quality of life of these patients. Longer studies with larger sample size are needed to study the long-term clinical effect of FPP® before it is recommended for daily use for patients with thalassaemia intermedia.
